Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026Score 9/3079% below fair value
$1.78−0.01 (-0.56%)
Close on Nov 13, 2026Market cap $19.34MP/E –Yield –
Aytu BioPharma operating margin
Operating margin is operating income as a percentage of revenue.
Aytu BioPharma's operating margin for the twelve months ending Jun 30, 2026 was -14.4%. For fiscal 2026 it was -14.4%, against -11.8% the year before. The highest annual figure on record is -2.4% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -14.4% | −2.7 |
| FY2025 | Jun 30, 2025 | -11.8% | −9.4 |
| FY2024 | Jun 30, 2024 | -2.4% | +13.4 |
| FY2023 | Jun 30, 2023 | -15.9% | +97.8 |
| FY2022 | Jun 30, 2022 | -113.7% | −24.0 |
| FY2021 | Jun 30, 2021 | -89.7% | −13.2 |
| FY2020 | Jun 30, 2020 | -76.5% | +153.7 |
| FY2019 | Jun 30, 2019 | -230.1% | +308.1 |
| FY2018 | Jun 30, 2018 | -538.2% | +86.5 |
| FY2017 | Jun 30, 2017 | -624.7% | +222.3 |
| FY2016 | Jun 30, 2016 | -847.0% | +2068.5 |
| FY2015 | Jun 30, 2015 | -2915.5% | +79.6 |
| FY2013 | Aug 31, 2013 | -2995.1% | +225.3 |
| FY2012 | Aug 31, 2012 | -3220.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -4.8% | +45.5 |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -32.7% | −45.9 |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -13.0% | −2.5 |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -10.8% | −5.2 |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -50.4% | −34.8 |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | 13.1% | +24.5 |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -10.4% | −27.2 |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -5.6% | −0.7 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -15.6% | −16.1 |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -11.4% | +26.3 |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | 16.8% | +42.9 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -4.9% | +1.7 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | 0.5% | +62.3 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -37.6% | +183.1 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -26.1% | +22.7 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -6.5% | +120.0 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -61.7% | +40.8 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -220.8% | −30.4 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -48.8% | −12.0 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -126.5% | −100.2 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -102.5% | −57.9 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -190.4% | −131.6 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -36.8% | +119.6 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -26.3% | +302.6 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -44.6% | +222.3 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -58.8% | +122.0 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -156.4% | +97.1 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -328.9% | −90.2 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -266.9% | +146.7 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -180.8% | +1057.9 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -253.5% | +126.4 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -238.7% | +166.0 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -413.6% | +196.5 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -1238.7% | −694.8 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -380.0% | +148.7 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -404.7% | +450.1 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -610.2% | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -543.9% | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -528.7% | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -854.8% | – |
See a number that looks wrong?